Octagon Capital Advisors as of Sept. 30, 2025
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 26 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads (ABVX) | 17.1 | $113M | 1.3M | 84.90 | |
| Dianthus Therapeutics (DNTH) | 14.4 | $95M | 2.4M | 39.35 | |
| Gossamer Bio (GOSS) | 6.8 | $45M | 17M | 2.63 | |
| Cogent Biosciences (COGT) | 6.3 | $41M | 2.9M | 14.36 | |
| Arrivent Biopharma (AVBP) | 5.5 | $36M | 2.0M | 18.45 | |
| Ocular Therapeutix (OCUL) | 4.6 | $31M | 2.6M | 11.69 | |
| Taysha Gene Therapies Com Shs (TSHA) | 4.5 | $30M | 9.1M | 3.27 | |
| Merus N V (MRUS) | 4.4 | $29M | 308k | 94.15 | |
| Cidara Therapeutics Com New (CDTX) | 4.4 | $29M | 300k | 95.76 | |
| Trevi Therapeutics (TRVI) | 3.9 | $26M | 2.8M | 9.15 | |
| Mind Medicine Mindmed Com New (MNMD) | 3.8 | $25M | 2.1M | 11.79 | |
| Apellis Pharmaceuticals (APLS) | 3.1 | $20M | 904k | 22.63 | |
| Kymera Therapeutics (KYMR) | 3.1 | $20M | 360k | 56.60 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 3.1 | $20M | 830k | 24.25 | |
| Pharvaris N V (PHVS) | 2.7 | $18M | 723k | 24.95 | |
| Kalvista Pharmaceuticals (KALV) | 2.4 | $16M | 1.3M | 12.18 | |
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.1 | $14M | 1.1M | 12.65 | |
| Bridgebio Oncology Therapeut Com New | 1.8 | $12M | 1.0M | 11.58 | |
| Dbv Technologies S A Sponsored Ads (DBVT) | 1.5 | $10M | 1.0M | 10.00 | |
| Nuvation Bio Com Cl A (NUVB) | 1.5 | $9.7M | 2.6M | 3.70 | |
| Maze Therapeatics (MAZE) | 0.7 | $4.6M | 178k | 25.93 | |
| Neurogene (NGNE) | 0.7 | $4.4M | 252k | 17.33 | |
| Unicycive Therapeutics Com New (UNCY) | 0.7 | $4.4M | 1.0M | 4.36 | |
| Pepgen (PEPG) | 0.5 | $3.2M | 700k | 4.62 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 0.5 | $3.2M | 115k | 28.00 | |
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.1 | $385k | 104k | 3.70 |
